Literature DB >> 28098862

Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells.

Guomei Zhou1, Fenghui Peng1, Yanping Zhong2, Yanhua Chen1, Min Tang1, Danrong Li1.   

Abstract

Matrix metalloproteinases (MMPs) are a family of calcium-dependent zinc-containing endopeptidases, which play an integral role in migration and invasion of ovarian cancer. Rac1 proteins might mostly influence cell migration and invasion by generating endogenous reactive oxygen species. Therefore, inhibiting MMPs and regulating the Rac1/ROS/MAPK/AP-1 pathway may be a new therapeutic strategy for ovarian cancer. In this study, we found that rhein could suppress the invasion and migration of SKOV3-PM4 cells with characteristics of directional highly lymphatic metastasis. Phorbol 12-myristate 13-acetate (PMA), which is a Rac1 activator, significantly enhanced the expression levels of MMP-2, -3, -9 and -19 proteins, whereas the results of rhein and Rac1 inhibitor NSC23766 were just the opposite. The inhibitory effects of rhein were associated with the upregulation of tissue inhibitors of metalloproteinase (TIMP)-1, TIMP-2 and NM23-H1. Subsequent mechanism studies revealed that rhein reduce the production of reactive oxygen species (ROS) and lower NADPH oxidase activity. Furthermore, rhein significantly inhibited JNK, AP-1 phosphorylation in the cells treated with PMA. The results obtained from the cells treated with NSC23766 alone or NSC23766 combined with rhein, were consistent with rhein treatment alone. Taken together, these results indicate that rhein may be a potential inhibitor of Rac1 and can inhibit the migration and invasion of SKOV3-PM4 cells through modulating matrix metalloproteinases and RAC1/ROS/MAPK/AP-1 signaling pathway-associated proteins.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28098862     DOI: 10.3892/ijo.2017.3853

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

Review 1.  Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Sci       Date:  2022-07-15       Impact factor: 2.924

Review 2.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 3.  The role and mechanism of β‑arrestins in cancer invasion and metastasis (Review).

Authors:  Qing Song; Qing Ji; Qi Li
Journal:  Int J Mol Med       Date:  2017-11-27       Impact factor: 4.101

Review 4.  Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties.

Authors:  Sahu Henamayee; Kishore Banik; Bethsebie Lalduhsaki Sailo; Bano Shabnam; Choudhary Harsha; Satti Srilakshmi; Naidu Vgm; Seung Ho Baek; Kwang Seok Ahn; Ajaikumar B Kunnumakkara
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

Review 5.  Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase.

Authors:  Laurie G Hudson; Jennifer M Gillette; Huining Kang; Melanie R Rivera; Angela Wandinger-Ness
Journal:  Cancers (Basel)       Date:  2018-09-27       Impact factor: 6.639

6.  Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor‑κB signaling pathway.

Authors:  Liu Yang; Qi Hong; Si-Guang Xu; Xia-Ying Kuang; Gen-Hong Di; Guang-Yu Liu; Jiong Wu; Zhi-Ming Shao; San-Jian Yu
Journal:  Mol Med Rep       Date:  2019-09-03       Impact factor: 2.952

7.  Hypermethylation of DLG3 Promoter Upregulates RAC1 and Activates the PI3K/AKT Signaling Pathway to Promote Breast Cancer Progression.

Authors:  Bingbing Liu; Yanning Xu; Lin Zhang; Xue Yang; Ling Chen; Yixin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-02       Impact factor: 2.629

8.  Rhein inhibits malignant phenotypes of human renal cell carcinoma by impacting on MAPK/NF-κB signaling pathways.

Authors:  Ya-Li Ma; Fang Chen; Jun Shi
Journal:  Onco Targets Ther       Date:  2018-03-14       Impact factor: 4.147

9.  Rhein Derivative 4F Inhibits the Malignant Phenotype of Breast Cancer by Downregulating Rac1 Protein.

Authors:  Xinxiao Li; Yunfeng Liu; Yuhua Zhao; Wei Tian; Lina Zhai; Huifeng Pang; Jiankang Kang; Huaxin Hou; Yanhua Chen; Danrong Li
Journal:  Front Pharmacol       Date:  2020-05-28       Impact factor: 5.810

10.  Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype.

Authors:  Zhuanli Bai; Yiping Qu; Lin Shi; Xinju Li; Zhen Yang; Meiju Ji; Peng Hou
Journal:  Cell Death Dis       Date:  2021-08-03       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.